Key facts
- This page summarizes William E. Duke's Form 4 filing for Kaleido Biosciences, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 Jan 2022, 16:11.
William E. Duke - 14 Jan 2022 Form 4 Insider Report for Kaleido Biosciences, Inc.
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 14 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Jan 2022, 16:11:18 UTC
- Prior SEC filing
- 02 Sep 2021
- Next SEC filing
- 08 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ William Duke, Jr.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William E. Duke filed Form 4 for Kaleido Biosciences, Inc. on 18 Jan 2022.
Change
- Previous filing in this sequence was filed on 02 Sep 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KLDO
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +44,990
- Change %
- Price
- $0.000000
- Shares after
- 44,990
- Date
- 14 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 44,990
- Exercise price
- Footnotes
- F1, F2
KLDO
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +125,000
- Change %
- Price
- $0.000000
- Shares after
- 125,000
- Date
- 14 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 125,000
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
Footnote F2
The restricted stock units shall vest 100% on April 30, 2022 provided, however, that the grant shall immediately vest as of the date of any change in control of the issuer.
Footnote F3
The restricted stock units shall vest on the earlier of 50% on January 14, 2023 and 50% on January 14, 2024 provided, however, that the grant shall immediately vest as of the date of any change in control of the issuer.